Evaluation of hematological and biochemical factors of hypertension during the induction chemotherapy for childhood acute lymphoblastic leukemia

Mousumi Saha; Chowdhury Yakub Jamal; Shahinoor Akter Soma; M. Imrul Kaes

doi:10.18203/2349-3291.ijcp20232875

Authors

Mousumi Saha Department of Pediatrics, Bangabandhu Sheikh Mujib Medical College Hospital, Faridpur, Bangladesh
Chowdhury Yakub Jamal Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka, Bangladesh
Shahinoor Akter Soma Department of Pediatric Hematology and Oncology, Shaheed Suhrawardy Medical College, Sher- EBangla Nagar, Dhaka, Bangladesh
M. Imrul Kaes Department of Pediatric Hematology and Oncology, Khwaja Yunus Ali Medical College, Sirajganj, Bangladesh

DOI:

https://doi.org/10.18203/2349-3291.ijcp20232875

Keywords:

Acute lymphoblastic leukemia, Hypertension, Induction chemotherapy, Hematological and biochemical

Abstract

Background: Acute lymphoblastic leukemia (ALL) is a prevalent childhood cancer, accounting for approximately 25% of all pediatric cancer cases. The incidence of hypertension in ALL patients is significantly higher compared to the general pediatric population, emphasizing the need for a better understanding and management of this condition. The aim of the study was to evaluate hematological and biochemical factors of hypertension during the induction of chemotherapy for childhood ALL.

Methods: This prospective observational study was conducted in the Department of Pediatric Hematology and Oncology at BSMMU from July 2017 to June 2018. The study included 93 newly diagnosed cases of ALL in children aged 1 to 17.9 years, excluding those below 1 year and above 18 years, known cases of hypertension, patients with pre-existing hypertension before chemotherapy, and old or relapse cases of ALL.

Results: The study found that 17.2% of the study population experienced renal derangement during the induction remission phase, while the majority (82.8%) did not. The presence of renal derangement was not significantly associated with hypertension. However, patients who developed tumor lysis syndrome (TLS) had a higher percentage (12.5%) of hypertension compared to the non-hypertensive group (1.3%). Febrile neutropenia, convulsion, and coagulopathy were also observed in patients who developed hypertension more frequently. The median time to detect hypertension during induction chemotherapy was on day 8, with a mean duration of 13.6 days.

Conclusions: In this study, hypertension is observed in 17.2% of patients during induction chemotherapy for ALL with higher frequency in the second week and associations with tumor lysis syndrome, febrile neutropenia, convulsion, and coagulopathy.

Metrics

Metrics Loading ...

References

Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G. Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transfus. 1987;30:139-46.

Arora RS, Arora B. Acute leukemia in children: A review of the current Indian data. South Asian J Cancer. 2016;5:155-60.

Islam A, Jamal CY, Nahar K, Siddique R, Begum F, Begum M, et al. Paediatric Oncology Data Based Network (POND) registry initiated in Bangladesh. Paediatr Blood Cancer. 2013;60:144-5.

Attard-Montalto SP, Saha V, Ng YY, Kingston JE, Eden OB. High incidence of hypertension in children presenting with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994;11(5):519-25.

Yetgin S, Olgar Ş, Aras T, Cetin M, Düzova A, Beylergil V, et al. Evaluation of kidney damage in patients with acute lymphoblastic leukemia in long-term follow-up: Value of renal scan. Am J Hematol. 2004;77(2):132-9.

Luciano RL, Brewster UC. Kidney involvement in leukemia and lymphoma. Adv Chron Kid Dis. 2014;21(1):27-35.

Louis CU, Butani L. High blood pressure and hypertension in children with newly diagnosed acute leukemia and lymphoma. Pediatr Nephrol. 2008;23(4):603-9.

Kamdem LK, Hamilton L, Cheng C, Liu W, Yang W, Julie A, et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2008;18:507-14.

Louis CU, Butani L. High blood pressure and hypertension in children with newly diagnosed acute leukemia and lymphoma. Pediatr Nephrol. 2008;23:603-9.

Attard-Montalto SP, Saha V, Ng YY, Kingston JE, Eden OB. High incidence of hypertension in children presenting with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1994;11:519-25.

Bakk I, O’Brien S, Reed S, Koch T. Steroid-induced hypertension during induction chemotherapy for acute lymphoblastic leukemia in US children’s hospitals. Blood. 2014;124:3651.

Juliansen A, Andriastuti M, Sudung OP, Sekartini R. Hypertension, high-dose corticosteroids, and renal infiltration in children with acute lymphoblastic leukemia. Paediatrica Indonesiana. 2014;54:324-9.

Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al-Jefri A, Alusa A, Saleh M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer. 2003;97:2898-903.

Kamdem LK, Hamilton L, Cheng C, Liu W, Yang W, Johnson JA, et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Geno. 2008;18(6):507-14.

Freiberg AS, Kees-Folts D, Dyer AM, Taylor M. 2008, Incidence and risk factors for hypertension during induction chemotherapy for pediatric acute lymphoblastic leukemia. Blood. 2008;112(11):3940.

Hoque M. Research methodology and biostatistics. Dhaka; ABC Publication; 2016.

Juliansen A, Andriastuti M, Pardede S, Sekartini R. Hypertension, high-dose corticosteroids, and renal infiltration in children with acute lymphoblastic leukemia. Paediatrica Indonesiana. 2014;54(6):372-6.

Bakk I, Koch T, Stanek J, O'brien SH, Reed S. Steroid-induced hypertension during induction chemotherapy for acute lymphoblastic leukemia in US Children's Hospitals. J Pediatr Hematol Oncol. 2018;40(1):27-30.

Olger S, Yetgin S, Cetin M, Aras T. Can renal leukemic infiltration cause hypertension in children? J Pediatr Hematol Oncol. 2006;28(9).

Hu M, Wang H, Lin K, Huang J, Hsia S, Chou M, et al. Clinical experience of childhood hypertensive encephalopathy over an eight year period. Chang Gung Med J. 2008;31(2):153.